Page 215 - Mployee Wellness Programs News Today

Brightside Health has launched a new program called Crisis Care, specifically designed for individuals with elevated suicide risk. It is initially rolling out in 27 states, with plans to expand across the nation.

Wearables company Movano Health recently partnered with Novant Health to beta test its smart ring — which is designed for women — with the health system’s employees. The program is expected to prepare Movano for its first direct-to-consumer product launch in the first half of next year.

As a daughter who has been through the wringer a few times, I write today to all health care leaders trying to build a better future.

We are approaching a new era for women’s health. This new era will usher in true transformation in both the delivery of care and the financial models that underpin it.

2023 is shaping up to be a crucial year for everyone involved – and affected – by the pharmaceutical industry. It's likely to be a year of experimentation for payers – and defensiveness for drug makers.

Healthcare institutions must make clear their seriousness about employee mental health support and overall wellbeing and take decisive actions to make things better.

Through the partnership, Superior's adult Medicaid population will have access to MedArrive's home care services. If a MedArrive provider notices that a patient could benefit from behavioral health services, that person can be referred to Brave Health.

Lovelace Medical Center in Albuquerque has recently established a virtual nursing program using Care.ai's technology. The solution enables virtual nurses to handle patient care and administrative tasks that don’t require physical proximity. Lovelace is adopting the technology to mitigate the nurse shortage and burnout crisis.

Payers and providers face different challenges when it comes to compliance. The volume of price transparency data that hospitals must disclose online amounts to about 3 terabytes — compared to the whopping 630 terabytes of data that payers have been tasked with posting.

Nearly all patients treated with the Novartis drug iptacopan achieved the hemoglobin goals of pivotal study compared to zero patients who received the AstraZeneca drugs that are the standard of care in a rare blood disorder. The results were presented Tuesday during the annual meeting of the American Society of Hematology.